LUM-201

Phase 3Small molecule

LLumos Pharma

LUM-201 is one of 103 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Growth Hormone DeficiencyRecruiting

GrowthActive, not recruiting

Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Growth Hormone DeficiencyPhase 3

Recruiting

GrowthPhase 2

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

LUM-201

LLumos Pharma

Phase 3

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Lenvima

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

Glucophage

2 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Growth Hormone Deficiency

NCT06948214

Q1 2030

Phase 3Not yet recruiting

Growth Hormone Deficiency

NCT07129759

Q3 2030

Phase 2Active, not recruiting

Growth Hormone Deficiency

NCT04806854

Clinical

Trials by Indication[1]

Growth Hormone Deficiency5 trials

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

Completed·LLumos Pharma·Phase 2·NCT04614337·82 enrolled

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Enrolling by invitation·LLumos Pharma·Phase 2·NCT05796440·60 enrolled

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

Active, not recruiting·LLumos Pharma·Phase 2·NCT04806854·24 enrolled

Show 2 more trials

A Long-term Extension Study to Evaluate the Safety and Tolerability of Daily Oral LUM-201 in Children With Growth Hormone Deficiency (GHD)

Not yet recruiting·LLumos Pharma·Phase 3·NCT07129759·150 enrolled

A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD)

Recruiting·LLumos Pharma·Phase 3·NCT06948214·150 enrolled

Alcoholic Fatty Liver Disease1 trial

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

Completed·MMassachusetts General Hospital·Phase 2·NCT05364684·12 enrolled

Growth1 trial

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

Completed·LLumos Pharma·Phase 2·NCT05250063·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for LUM-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LUM-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LUM-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lumos Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLumos Pharma

LUM-201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2030

Q3 2030

Trials by Indication[1]

Growth Hormone Deficiency5 trials

Alcoholic Fatty Liver Disease1 trial

Growth1 trial

References

Drug Info

Quick Facts

Related News